A new imaging agent could let doctors identify not only multiple types of tumors but the surrounding normal cells that cancers take over and use as a shield to protect from destruction, researchers report.
The imaging agent, referred to as LS301, has received approval for investigational use in small clinical trials at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine. The first trial will investigate its use in imaging breast cancer.
“This unique imaging agent identifies cancer cells as well as other compromised cells surrounding the tumor,” says Samuel Achilefu, professor of of radiology at the Washington University School of Medicine.
“We were amazed when we saw this because it’s extremely difficult to access anything inside a tumor,”
“Cancer transforms surrounding cells so that it can proliferate, spread to other parts of the body, and escape treatment. This imaging compound can detect cancer cells and their supporting cast, the diseased cells that are otherwise invisible.”
The compound binds to the activated form of a protein called annexin A2, which is present in many types of solid tumors but not healthy tissue. The activated form of the protein promotes inflammation and invasiveness of these tumors, which allows the cancer to spread.
Solid tumors that contain activated annexin A2 are found in breast, colon, liver, pancreatic, head and neck, and brain cancers. Since the activated form of the protein also is present in the cells that surround the tumor—and not normal, healthy cells—doctors potentially could use this imaging agent to identify cells the tumor has hijacked. Despite their benign status, these hijacked cells protect the tumor from chemotherapy, radiation and other attempts to kill the cancer cells. Such co-opted cells also conceal cancer stem cells, whose stealth presence can lead to a recurrence of the tumor.
“We are coming to the realization that to eradicate cancer, we also need to focus on the microenvironment of the tumor,” says Achilefu, who also directs the university’s Optical Radiology Lab at the Mallinckrodt Institute of Radiology and is co-leader of the Oncologic Imaging Program at Siteman. “Most cancer drugs are designed to target cancer cells. But cancer cells create their own fiefdom, where they impose their own rules. If a normal cell nearby wants to continue living, it must follow the new rules. And slowly these cells come to identify with the tumor rather than their normal identity.”
Achilefu expects that with a tumor and its surrounding fiefdom illuminated by the new imaging agent, doctors would have a better chance of removing the entire tumor as well as any areas that are likely to harbor microscopic cancer cells.
In past work, Achilefu’s team has developed cancer goggles that allow surgeons to visualize cancer cells in real time during surgery to remove a tumor. The new imaging agent can be used with these goggles, which researchers are evaluating in clinical trials. The researchers also are working on a version of the compound that could be useful in positron emission tomography (PET) scans, which many cancer patients undergo to assess whether cancer has spread.
As Achilefu and his colleagues saw that the compound lit up the hijacked cells on the periphery of the tumor, seeing the imaging agent light up parts of the central core of the tumor as well came as a surprise.
“We were amazed when we saw this because it’s extremely difficult to access anything inside a tumor,” Achilefu says. “There seems to be a type of immune cell that carries the imaging agent into the core of the tumor. So we now see the tumor margin and the core light up.
“This allows us to imagine a situation in which we could deliver a drug to the outside and the inside of the tumor at the same time. This dual targeting is not something we purposefully designed — it’s not something we ever anticipated.”
With this in mind, Achilefu’s team conducted mouse studies to show that the researchers can attach a chemotherapy drug to the compound and use it to image the tumor and treat the disease simultaneously.
“Attaching a chemotherapy drug to this targeted imaging agent could reduce side effects as we are delivering the drug directly to the tumor,” he says. “If the clinical trials are successful with the imaging, we will move into therapy.”
The study appears in Nature Biomedical Engineering.
Support for the study came from the National Cancer Institute (NCI), the National Institutes of Health (NIH), the Department of Defense Breast Cancer Research Program, and the Alvin J. Siteman Cancer Research Fund. Further support came from the Alvin J. Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital in St. Louis, and the Institute of Clinical and Translational Sciences at Washington University, through the use of the Tissue Procurement Core, which provided tissues of human breast cancer patients. Gabriel Birrane provided purified ANXA2 and pANXA2 protein reagents used in the initial study.
Achilefu is a co-inventor on a US patent issued to Washington University covering LS301. The patent may become the subject of a licensing agreement in the future.
